Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive to talk through significant progress in the journey of RECCE® 327...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is developing new classes of synthetic...
Race Oncology Ltd (ASX:RAC) is advancing its Phase 2/3 cancer drug Zantrene which is a potent...
A study led by the Walter and Eliza Hall Institute of Medical Research (WEHI) and the Peter...
The Highway Patrol may soon be testing for driving impairment via sleep deprivation as well as...
MMJ Group Holdings Ltd (ASX:MMJ) has maintained its investment strategy in 2020 with company...
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive to talk through significant progress in the journey of RECCE® 327 (R327) for treating urinary tract infections (UTI) and urosepsis. The company has completed dosing in its Phase 1/2 clinical trial, which focused on...